TY - JOUR
T1 - Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study
AU - Jensen, Poul Erik H.
AU - Warnke, Clemens
AU - Ingenhoven, Kathleen
AU - Piccoli, Luca
AU - Gasis, Marcia
AU - Hermanrud, Christina
AU - Fernandez-Rodriguez, Blanca M.
AU - Ryner, Malin
AU - Kramer, Daniel
AU - Link, Jenny
AU - Ramanujam, Ryan
AU - Auer, Michael
AU - Buck, Dorothea
AU - Grummel, Verena
AU - Bertotti, Elisa
AU - Fissolo, Nicolas
AU - Oliver-Martos, Begoña
AU - Nytrova, Petra
AU - Khalil, Michael
AU - Guger, Michael
AU - Rathmaier, Sandra
AU - Sievers-Stober, Claudia
AU - Lindberg, Raija L.P.
AU - Hässler, Signe
AU - Bachelet, Delphine
AU - Aktas, Orhan
AU - Donnellan, Naoimh
AU - Lawton, Andy
AU - Hemmer, Bernhard
AU - Havrdova, Eva Kubala
AU - Kieseier, Bernd
AU - Hartung, Hans Peter
AU - Comabella, Manuel
AU - Montalban, Xavier
AU - Derfuss, Tobias
AU - Sellebjerg, Finn
AU - Dönnes, Pierre
AU - Pallardy, Marc
AU - Spindeldreher, Sebastian
AU - Broët, Philippe
AU - Deisenhammer, Florian
AU - Fogdell-Hahn, Anna
AU - Sorensen, Per Soelberg
N1 - Publisher Copyright:
© 2018 Elsevier B.V.
PY - 2019/1/15
Y1 - 2019/1/15
N2 - Two validated assays, a bridging ELISA and a luciferase-based bioassay, were compared for detection of anti-drug antibodies (ADA) against interferon-beta (IFN-β) in patients with multiple sclerosis. Serum samples were tested from patients enrolled in a prospective study of 18 months. In contrast to the ELISA, when IFN-β-specific rabbit polyclonal and human monoclonal antibodies were tested, the bioassay was the more sensitive to detect IFN-β ADA in patients' sera. For clinical samples, selection of method of ELISA should be evaluated prior to the use of a multi-tiered approach. A titer threshold value is reported that may be used as a predictor for persistently positive neutralizing ADA.
AB - Two validated assays, a bridging ELISA and a luciferase-based bioassay, were compared for detection of anti-drug antibodies (ADA) against interferon-beta (IFN-β) in patients with multiple sclerosis. Serum samples were tested from patients enrolled in a prospective study of 18 months. In contrast to the ELISA, when IFN-β-specific rabbit polyclonal and human monoclonal antibodies were tested, the bioassay was the more sensitive to detect IFN-β ADA in patients' sera. For clinical samples, selection of method of ELISA should be evaluated prior to the use of a multi-tiered approach. A titer threshold value is reported that may be used as a predictor for persistently positive neutralizing ADA.
KW - Anti-drug antibodies
KW - Bridging ELISA
KW - Interferon-beta
KW - Luciferase-based bioassay
KW - Multiple sclerosis
KW - Neutralizing antibodies
UR - http://www.scopus.com/inward/record.url?scp=85056449193&partnerID=8YFLogxK
U2 - 10.1016/j.jneuroim.2018.11.002
DO - 10.1016/j.jneuroim.2018.11.002
M3 - Article
C2 - 30447419
AN - SCOPUS:85056449193
SN - 0165-5728
VL - 326
SP - 19
EP - 27
JO - Journal of Neuroimmunology
JF - Journal of Neuroimmunology
ER -